Citadel Advisors
COLL icon

Citadel Advisors’s Collegium Pharmaceutical COLL Stock Holding History

Citadel Advisors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.01M Sell
121,366
-9,760
-7% -$413K ﹤0.01% 4706
2025
Q4 		$6.07M Sell
131,126
-122,374
-48% -$5.12M ﹤0.01% 3980
2025
Q3 		$8.87M Buy
253,500
+13,344
+6% +$464K ﹤0.01% 3452
2025
Q2 		$7.1M Sell
240,156
-269,999
-53% -$7.7M ﹤0.01% 3526
2025
Q1 		$15.2M Buy
510,155
+157,184
+45% +$4.8M ﹤0.01% 2339
2024
Q4 		$10.1M Buy
352,971
+221,627
+169% +$7.33M ﹤0.01% 2973
2024
Q3 		$5.08M Sell
131,344
-41,326
-24% -$1.47M ﹤0.01% 3913
2024
Q2 		$5.56M Buy
172,670
+59,927
+53% +$2.08M ﹤0.01% 3583
2024
Q1 		$4.38M Buy
112,743
+2,235
+2% +$78.2K ﹤0.01% 4145
2023
Q4 		$3.4M Buy
+110,508
New +$2.77M ﹤0.01% 4438
2023
Q3 		– Sell
-76,543
Closed -$1.64M – 14373
2023
Q2 		$1.64M Sell
76,543
-109,820
-59% -$2.49M ﹤0.01% 5509
2023
Q1 		$4.47M Buy
186,363
+64,241
+53% +$1.7M ﹤0.01% 3996
2022
Q4 		$2.83M Buy
122,122
+12,733
+12% +$257K ﹤0.01% 4847
2022
Q3 		$1.75M Sell
109,389
-54,918
-33% -$968K ﹤0.01% 5836
2022
Q2 		$2.91M Buy
164,307
+57,782
+54% +$972K ﹤0.01% 4807
2022
Q1 		$2.17M Buy
+106,525
New +$2.01M ﹤0.01% 5912
2021
Q4 		– Sell
-23,933
Closed -$473K – 13881
2021
Q3 		$473K Buy
23,933
+3,261
+16% +$70.5K ﹤0.01% 10006
2021
Q2 		$489K Sell
20,672
-29,685
-59% -$686K ﹤0.01% 10108
2021
Q1 		$1.19M Sell
50,357
-63,309
-56% -$1.5M ﹤0.01% 7662
2020
Q4 		$2.28M Buy
113,666
+38,924
+52% +$760K ﹤0.01% 5094
2020
Q3 		$1.56M Buy
74,742
+53,096
+245% +$958K ﹤0.01% 5197
2020
Q2 		$379K Sell
21,646
-125,519
-85% -$2.46M ﹤0.01% 7533
2020
Q1 		$2.4M Buy
+147,165
New +$3.04M ﹤0.01% 3851
2019
Q4 		– Sell
-10,873
Closed -$125K – 9178
2019
Q3 		$125K Sell
10,873
-23,230
-68% -$265K ﹤0.01% 8382
2019
Q2 		$448K Sell
34,103
-124,884
-79% -$1.67M ﹤0.01% 6993
2019
Q1 		$2.41M Buy
158,987
+49,668
+45% +$795K ﹤0.01% 4149
2018
Q4 		$1.88M Sell
109,319
-81,437
-43% -$1.39M ﹤0.01% 4241
2018
Q3 		$2.81M Buy
190,756
+170,197
+828% +$3.02M ﹤0.01% 3840
2018
Q2 		$490K Sell
20,559
-318,250
-94% -$7.83M ﹤0.01% 6406
2018
Q1 		$8.66M Sell
338,809
-521,918
-61% -$12.4M ﹤0.01% 1872
2017
Q4 		$15.9M Buy
860,727
+316,694
+58% +$4.54M 0.01% 1325
2017
Q3 		$5.71M Buy
544,033
+493,671
+980% +$5.44M ﹤0.01% 2167
2017
Q2 		$630K Sell
50,362
-19,547
-28% -$193K ﹤0.01% 4787
2017
Q1 		$703K Buy
+69,909
New +$1.04M ﹤0.01% 4499

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Citadel Advisors's COLL Position: Q1 2026 in Review

Citadel Advisors reduced its Collegium Pharmaceutical (COLL) stake by 7.4% in Q1 2026, selling an estimated $413K and leaving 121,366 shares worth $4.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4706.

Citadel Advisors first reported a position in COLL in Q1 2017 and has held it in 34 quarters since. The position peaked at $15.9M in Q4 2017. 266 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

  • Citadel Advisors held 121,366 shares of Collegium Pharmaceutical worth $4.01M as of Q1 2026.
  • Citadel Advisors sold 9,760 Collegium Pharmaceutical shares in Q1 2026, an estimated $413K.
  • Collegium Pharmaceutical made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4706 holding.
  • Citadel Advisors first reported a position in Collegium Pharmaceutical in Q1 2017 and has held it in 34 quarters since.
  • Citadel Advisors's Collegium Pharmaceutical position peaked at $15.9M in Q4 2017.
  • 266 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.